ETH Meets Boston 2019
Boston, 18 October 2019 - RETHINK Drug Discovery. This public event will address the latest advances in the field of artificial intelligence and drug discovery.
RETHINK Drug Discovery
Recent advances in chemical synthesis, biological testing, and artificial intelligence (AI) allow for greater automation in the drug discovery process. AI systems that generate novel design suppositions, as well as, cope with multiple design objectives provide a basis for further automation in some aspects of drug discovery. Automation could potentially accelerate timeframes for compound design and optimization. It could also enable better decision making in early-stage pharmaceutical discovery that translates into late-stage clinical validation. However, such approaches also raise considerable conceptual, technical, and organizational challenges.
This symposium aims to address the latest advances of this rapidly progressing field of science, by bringing together leading researchers to present the state-of-the-art in drug discovery. Together they will make daring predictions surrounding the possibilities and limitations of drug discovery using machine intelligence.
Public event
Friday, October 18, 2019
6.30 pm
Door opening time: 6.00 pm
Venue
external pageDistrict Hallcall_made
75 Northern Avenue, Boston, MA
RSVP
Free entry. Please register external pageherecall_made.
Programme
DownloadDownload (PDF, 598 KB)vertical_align_bottom
Moderator
external pageSusan Kishcall_made
Executive, entrepreneur, advisor
Speakers
external pageAimee Useracall_made
Senior Investigator, Novartis Institutes for BioMedical Research (NIBR)
Gisbert Schneider
Professor for Computer-Assisted Drug Design, ETH Zurich
external pageConnor W. Coleycall_made
Postdoc, Broad Institute, MIT
external pageMarcie Glicksmancall_made
Chief Scientific Officer, ORIG3N